In 2025 BioMark Diagnostics Inc. significantly expanded its laboratory infrastructure, doubling throughput capacity to meet a surge in clinical and commercial testing demand. The company submitted ISO 15189 certification documents in December 2025 as a strategic precursor to CLIA and CAP accreditation for U.S. market entry. BioMark was selected as the exclusive partner for the HANSE trial, the largest prospective lung cancer study since 2013, providing unprecedented access to longitudinal data from 10,000 participants. Concurrently, the company completed Canada’s largest lung cancer diagnostic study with over 7,000 patients, generating robust real-world evidence and validating key biomarker panels. Investment in AI and machine learning strengthened diagnostic accuracy, while six peer-reviewed publications and the CQDM Innovation Prize underscored scientific leadership in metabolomics and AI-based oncology diagnostics.

BioMark secured $4.5 million in capital during a challenging small-cap market environment, reflecting strong investor confidence. The company obtained European expansion funding through NRC Horizon Europe and additional support from the City of Quebec. A Manitoba Lung Association grant launched a pilot lung cancer detection program for First Nations communities, advancing health equity initiatives. Submission of a letter of intent for Québec RNA Hub funding positions BioMark to develop its miRNA-LNP platform for RNA therapeutics under the AReNA program. These diversified funding sources and partnerships enhance the company’s revenue model and de-risk regulatory pathways, setting the stage for broader commercialization.

Key upcoming milestones include obtaining ISO 15189 accreditation to unlock CLIA/CAP applications and launching a U.S. reimbursement strategy in collaboration with screening centers and payors. BioMark plans to broaden its intellectual property estate, strengthen patent coverage for biomarker discovery, and publish landmark results from the HANSE 10,000-patient trial and the 7,000-patient Canadian study. Commercial activities will focus on negotiating licensing agreements with major pharmaceutical and diagnostics firms, launching ISO-certified laboratory services and CRO offerings, and expanding distribution through medical and clinic chains. Leadership hires for patient engagement, revenue generation, and a medical director will support scale-up and U.S. market entry.

On December 22, 2025, BioMark’s shareholders elected Mr. James Lavender to the Board of Directors. Lavender, a major investor in BioMark’s March financing, brings extensive software development, enterprise sales experience, and AI-driven growth strategy expertise. His network with state-level organizations and strategic investment groups across the United States is expected to accelerate U.S. market access and commercialization. CEO Rashid Ahmed Bux highlighted Lavender’s role in enhancing automation and scalability of the company’s metabolomics-based oncology diagnostics platform as critical to executing the commercialization roadmap and growing the lab services footprint.